BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19206087)

  • 1. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.
    Rowan C; Brinker AD; Nourjah P; Chang J; Mosholder A; Barrett JS; Avigan M
    Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):301-9. PubMed ID: 19206087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.
    Page SR; Yee KC
    Intern Med J; 2014 Jul; 44(7):690-3. PubMed ID: 25041770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.
    Gruer PJ; Vega JM; Mercuri MF; Dobrinska MR; Tobert JA
    Am J Cardiol; 1999 Oct; 84(7):811-5. PubMed ID: 10513779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
    Molden E; Skovlund E; Braathen P
    Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center.
    Karimi S; Hough A; Beckey C; Parra D
    J Manag Care Pharm; 2010 Sep; 16(7):472-81. PubMed ID: 20726676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
    Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
    Bakhai A; Rigney U; Hollis S; Emmas C
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhabdomyolysis in association with simvastatin and amiodarone.
    Roten L; Schoenenberger RA; Krähenbühl S; Schlienger RG
    Ann Pharmacother; 2004 Jun; 38(6):978-81. PubMed ID: 15069169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
    Strandell J; Bate A; Hägg S; Edwards IR
    Br J Clin Pharmacol; 2009 Sep; 68(3):427-34. PubMed ID: 19740401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
    Maxa JL; Melton LB; Ogu CC; Sills MN; Limanni A
    Ann Pharmacother; 2002 May; 36(5):820-3. PubMed ID: 11978159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.
    Andreou ER; Ledger S
    Can J Clin Pharmacol; 2003; 10(4):172-4. PubMed ID: 14712320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Brown urine : Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone].
    Pietsch U; Müller-Höcker C; Filipovic M
    Anaesthesist; 2016 May; 65(5):366-8. PubMed ID: 27142363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
    Saw J; Brennan DM; Steinhubl SR; Bhatt DL; Mak KH; Fox K; Topol EJ;
    J Am Coll Cardiol; 2007 Jul; 50(4):291-5. PubMed ID: 17659194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin.
    Sawant RD
    Can J Clin Pharmacol; 2009; 16(1):e78-9. PubMed ID: 19151423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin-induced rhabdomyolysis.
    Schreiber DH; Anderson TR
    J Emerg Med; 2006 Aug; 31(2):177-80. PubMed ID: 17044581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin-fluconazole causing rhabdomyolysis.
    Shaukat A; Benekli M; Vladutiu GD; Slack JL; Wetzler M; Baer MR
    Ann Pharmacother; 2003; 37(7-8):1032-5. PubMed ID: 12841814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins.
    Montastruc JL
    Br J Clin Pharmacol; 2023 Aug; 89(8):2636-2638. PubMed ID: 37186323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.